SecSonar.com

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Karyopharm Therapeutics Inc. (KPTI) is a Biotechnology company based in US with a market capitalization of $77.4M. Revenue grew 0.6% year-over-year and free cash flow was negative at -$75.4M. This page tracks KPTI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 279 employees · IPO Nov 6, 2013

Valuation

Valuation & price

$7.67 · as of May 17, 2026 · -24.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$10.21$7.01$3.81Jul 25Dec 25Jun 26Jul 7, 25$4.23Jul 9, 25$4.81Jul 11, 25$4.55Jul 15, 25$4.24Jul 17, 25$4.07Jul 21, 25$4.02Jul 23, 25$4.86Jul 25, 25$4.35Jul 29, 25$4.13Jul 31, 25$3.81Aug 4, 25$4.02Aug 6, 25$4.03Aug 8, 25$3.94Aug 12, 25$4.02Aug 14, 25$4.65Aug 18, 25$5.59Aug 20, 25$6.50Aug 22, 25$6.30Aug 26, 25$7.46Aug 28, 25$7.68Sep 3, 25$7.08Sep 5, 25$6.60Sep 9, 25$6.33Sep 11, 25$6.64Sep 15, 25$6.26Sep 17, 25$6.08Sep 19, 25$5.41Sep 23, 25$7.48Sep 25, 25$6.66Sep 29, 25$6.35Oct 1, 25$6.21Oct 3, 25$6.38Oct 7, 25$5.77Oct 9, 25$5.82Oct 13, 25$5.62Oct 15, 25$5.95Oct 17, 25$5.93Oct 21, 25$6.43Oct 23, 25$6.19Oct 27, 25$6.42Oct 30, 25$5.96Nov 3, 25$6.07Nov 5, 25$5.36Nov 7, 25$5.16Nov 11, 25$5.46Nov 13, 25$5.50Nov 17, 25$5.79Nov 19, 25$5.98Nov 21, 25$5.90Nov 25, 25$5.45Nov 28, 25$5.62Dec 2, 25$5.36Dec 4, 25$5.91Dec 8, 25$5.89Dec 10, 25$6.48Dec 12, 25$6.95Dec 16, 25$6.33Dec 18, 25$6.37Dec 22, 25$7.27Dec 24, 25$7.47Dec 29, 25$7.34Jan 2, 26$7.19Jan 6, 26$7.35Jan 8, 26$8.17Jan 12, 26$8.20Jan 14, 26$7.19Jan 16, 26$6.31Jan 21, 26$6.32Jan 23, 26$6.59Jan 27, 26$7.05Jan 29, 26$6.63Feb 2, 26$6.31Feb 4, 26$6.30Feb 6, 26$6.26Feb 10, 26$6.59Feb 12, 26$8.94Feb 17, 26$9.40Feb 19, 26$9.67Feb 23, 26$10.03Feb 25, 26$10.09Mar 2, 26$9.59Mar 4, 26$9.15Mar 6, 26$8.77Mar 10, 26$8.23Mar 12, 26$7.90Mar 16, 26$8.55Mar 18, 26$8.40Mar 20, 26$7.63Mar 24, 26$5.44Mar 26, 26$5.57Mar 30, 26$5.30Apr 1, 26$5.82Apr 6, 26$6.32Apr 8, 26$7.25Apr 10, 26$8.00Apr 14, 26$8.45Apr 16, 26$8.66Apr 20, 26$8.94Apr 22, 26$9.55Apr 24, 26$8.66Apr 28, 26$8.60May 1, 26$8.77May 5, 26$9.41May 7, 26$8.85May 11, 26$8.81May 13, 26$8.85May 15, 26$7.67May 19, 26$7.47May 21, 26$8.06May 26, 26$8.97May 28, 26$9.11Jun 1, 26$9.82Jun 3, 26$9.00Jun 5, 26$9.08Jun 9, 26$8.69Jun 11, 26$9.00Jun 15, 26$9.64Jun 17, 26$9.40Jun 22, 26$9.00Jun 26, 26$10.21
$3.7752-week range$10.21
Loading valuation history…

Fundamentals

Key fundamentals

$77.4M

Market cap

0.6%

Revenue growth (YoY)

95.9%

Gross margin

-$75.4M

Free cash flow (USD)

$169.9M

Net debt

34.6%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$154.0KFY 2017$1.6MFY 2018$30.3MFY 2019$40.9MFY 2020$108.1MFY 2021$209.8MFY 2022$157.1MFY 2023$146.0MFY 2024$145.2MFY 2025$146.1M
$154K$146.1M

Free cash flow by year

2016 → 2025

FY 2016$-84.5MFY 2017$-73.8MFY 2018$-161.5MFY 2019$-191.0MFY 2020$-160.4MFY 2021$-112.8MFY 2022$-149.7MFY 2023$-92.7MFY 2024$-127.6MFY 2025$-75.4M
-$84.5M-$75.4M

Gross margin by year

2021 → 2025

FY 202198.4%FY 202296.7%FY 202396.6%FY 202495.9%FY 202595.9%
98.4%95.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $-1.24)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEquity Incentive Plan AmendmentMay 28, 2026Filing
  • Insider sellInsider Sell $3KMano Michael · EVP, CLO&Secretary · $2.5KMay 15, 2026Filing
  • Insider sellInsider Sell $21KPaulson Richard A. · Director, President and CEO · $20.9KMay 15, 2026Filing
  • Insider sellInsider Sell $504Abate Kristin · Chief Accounting Officer · $503.5May 15, 2026Filing
  • Insider sellInsider Sell $3KCheng Sohanya Roshan · EVP & Chief Commercial Officer · $3.1KMay 15, 2026Filing
  • Insider sellInsider Sell $4KRangwala Reshma · EVP & Chief Medical Officer · $3.9KMay 15, 2026Filing
  • Insider sellInsider Sell $4KPoulton Stuart · EVP, Chief Development Officer · $3.8KMay 15, 2026Filing
  • 8-K eventEarnings ReleaseMay 14, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • FinancingSecurities RegistrationMay 4, 2026Filing

Questions

Frequently asked questions

What is Karyopharm Therapeutics Inc.'s market cap?

Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $77.4M.

What is KPTI's P/E ratio?

A meaningful P/E ratio is not available for KPTI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

When did Karyopharm Therapeutics Inc. last report earnings?

KPTI last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying KPTI stock?

SEC Form 4 filings show no open-market insider buys at Karyopharm Therapeutics Inc. in the last 90 days (7 sells).

Same arena

Related companies in Biotechnology

PLRX

Pliant Therapeutics, Inc.

$78M

NRXP

NRx Pharmaceuticals, Inc.

$78.1M

RLYB

Rallybio Corporation

$76.3M

CSBR

Champions Oncology, Inc.

$81M

MCRB

Seres Therapeutics, Inc.

$73.1M

HYFT

MindWalk Holdings Corp.

$82M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.